 REDWOOD CITY, Calif., May 20, 2022 GLOBE NEWSWIRE -- Biomea Fusion, Inc. Nasdaq: BMEA, a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Biomea will attend the H.C. Wainwright Global Investment Conference virtually and will participate in 1x1 meetings held by the conference organizers. 